About: Tafasitamab

Property	Value
dbo:abstract	Tafasitamab, sold under the brand name Monjuvi, is a medication used in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Tafasitamab may cause serious side effects including infusion related reactions, bone marrow suppression, infections, and harm to an unborn baby. The most common side effects of tafasitamab are low blood cell counts, fatigue, diarrhea, cough, fever, limb swelling, upper respiratory infection, and decreased appetite. Tafasitamab is a humanized Fc-modified cytolytic CD19 antibody. Tafasitamab was approved for medical use in the United States in July 2020. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. Tafasitamab represents an option for patients ineligible for CAR-T cell therapy. (en) Тафаситамаб — лекарственный препарат, моноклональное антитело для лечения диффузной B-крупноклеточной лимфомы. Одобрен для применения: США (2020). (ru)
dbo:alternativeName	Monjuvi, Minjuvi (en)
dbo:casNumber	1422527-84-1
dbo:drugbank	DB15044
dbo:fdaUniiCode	QQA9MLH692
dbo:kegg	D11601
dbo:wikiPageExternalLink	https://druginfo.nlm.nih.gov/drugportal/name/tafasitamab
dbo:wikiPageID	64703451 (xsd:integer)
dbo:wikiPageLength	9011 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1090937425 (xsd:integer)
dbo:wikiPageWikiLink	dbr:International_nonproprietary_name dbr:Lenalidomide dbc:Orphan_drugs dbr:Food_and_Drug_Administration dbc:Monoclonal_antibodies dbr:Diffuse_large_B-cell_lymphoma dbr:CD19 dbr:Humanized_antibody dbr:First-in-class_medication dbr:Intravenous
dbp:atcPrefix	L01 (en)
dbp:atcSuffix	FX12 (en)
dbp:c	6550 (xsd:integer)
dbp:casNumber	1422527 (xsd:integer)
dbp:dailymedid	Tafasitamab (en)
dbp:drugbank	DB15044 (en)
dbp:h	10092 (xsd:integer)
dbp:kegg	D11601 (en)
dbp:legalCa	Rx-only (en)
dbp:legalEu	Rx-only (en)
dbp:legalUs	Rx-only (en)
dbp:mabType	mab (en)
dbp:n	1724 (xsd:integer)
dbp:o	2048 (xsd:integer)
dbp:routesOfAdministration	dbr:Intravenous
dbp:s	52 (xsd:integer)
dbp:source	zu/o (en)
dbp:synonyms	tafasitamab-cxix, MOR208, Xmab5574 (en)
dbp:target	dbr:CD19
dbp:tradename	Monjuvi, Minjuvi (en)
dbp:type	mab (en)
dbp:unii	QQA9MLH692 (en)
dbp:wikiPageUsesTemplate	dbt:Antineoplastic-drug-stub dbt:Cite_web dbt:Infobox_drug dbt:Portal_bar dbt:Reflist dbt:Short_description dbt:Use_American_English dbt:Use_dmy_dates dbt:Drugs.com dbt:ClinicalTrialsGov dbt:Monoclonal-antibody-stub
dcterms:subject	dbc:Orphan_drugs dbc:Monoclonal_antibodies
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody dbo:Drug
rdfs:comment	Тафаситамаб — лекарственный препарат, моноклональное антитело для лечения диффузной B-крупноклеточной лимфомы. Одобрен для применения: США (2020). (ru) Tafasitamab, sold under the brand name Monjuvi, is a medication used in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Tafasitamab may cause serious side effects including infusion related reactions, bone marrow suppression, infections, and harm to an unborn baby. The most common side effects of tafasitamab are low blood cell counts, fatigue, diarrhea, cough, fever, limb swelling, upper respiratory infection, and decreased appetite. Tafasitamab is a humanized Fc-modified cytolytic CD19 antibody. (en)
rdfs:label	Tafasitamab (en) Тафаситамаб (ru)
owl:sameAs	wikidata:Tafasitamab dbpedia-ru:Tafasitamab https://global.dbpedia.org/id/FbedJ
prov:wasDerivedFrom	wikipedia-en:Tafasitamab?oldid=1090937425&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:Tafasitamab
is dbo:wikiPageRedirects of	dbr:Tafasitamab-cxix dbr:Monjuvi dbr:Minjuvi
is dbo:wikiPageWikiLink of	dbr:Gilles_Salles dbr:MorphoSys dbr:Tafasitamab-cxix dbr:ATC_code_L01 dbr:Monjuvi dbr:Diffuse_large_B-cell_lymphoma dbr:Incyte dbr:List_of_therapeutic_monoclonal_antibodies dbr:Minjuvi
is foaf:primaryTopic of	wikipedia-en:Tafasitamab